Cytodyn Inc (CYDY)

[Saltz]

The timing of this non dilutive raise points to an uplist timed w trial results. Readout from M2M and possible halting of S2C due to mobility are the 1-2 punch to fuel a successful Nasdaq uplist.

I don’t want to put the cart in front of the horse but given the Covid data up to this point I would be shocked w anything short of amazing trial results. Dr. Patterson’s extreme confidence coupled w Dr. Lalezari’s home run opinion isn’t based on hype it’s based on blood work and firsthand knowledge. IMO the S2C death rate in the placebo arm compared to the drug arm is going to be so lopsided even Fauchi will have to take notice not o mention the FDA.

The terms of this latest raise is placing $28.5M in Naders hands and ultimately costing 2.85M shares. Just last year that would have cost SH’s a shade under 100M shares plus warrants. That’s a helluva deal for the company and it’s SH’s at this juncture and IMO gets us off the OTC.

The stars have aligned and anyone betting against this company is going to get run over. Let the fear mongers monger. Tick-Tock.